Investigating the specific uptake of EGF-conjugated nanoparticles in lung cancer cells using fluorescence imaging

Targeted nanoparticles have the potential to deliver a large drug payload specifically to cancer cells. Targeting requires that a ligand on the nanoparticle surface interact with a specific membrane receptor on target cells. However, the contribution of the targeting ligand to nanoparticle delivery is often influenced by non-specific nanoparticle uptake or secondary targeting mechanisms. In this study, we investigate the epidermal growth factor (EGF) receptor-targeting specificity of a nanoparticle by dual-color fluorescent labeling. The targeted nanoparticle was a fluorescently labeled, EGF-conjugated HDL-like peptide–phospholipid scaffold (HPPS) and the cell lines expressed EGF receptor linked with green fluorescent protein (EGFR-GFP). Using LDLA7 cells partially expressing EGFR-GFP, fluorescence imaging demonstrated the co-internalization of EGFR-GFP and EGF-HPPS, thus validating its targeting specificity. Furthermore, specific EGFR-mediated uptake of the EGF-HPPS nanoparticle was confirmed using human non-small cell lung cancer A549 cells. Subsequent confocal microscopy and flow cytometry studies delineated how secondary targeting mechanisms affected the EGFR targeting. Together, this study confirms the EGFR targeting of EGF-HPPS in lung cancer cells and provides insight on the potential influence of unintended targets on the desired ligand–receptor interaction.

[1]  J. Doroshow Targeting EGFR in non-small-cell lung cancer. , 2005, The New England journal of medicine.

[2]  R. Senekowitsch-Schmidtke,et al.  In vivo evaluation of epidermal growth factor (EGF) receptor density on human tumor xenografts using radiolabeled EGF and anti-(EGF receptor) mAb 425 , 1996, Cancer Immunology, Immunotherapy.

[3]  Hui Li,et al.  Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Ståhl,et al.  Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry , 2009, Journal of Nuclear Medicine.

[5]  Warren C W Chan,et al.  Nanoparticle-mediated cellular response is size-dependent. , 2008, Nature nanotechnology.

[6]  J. Xie,et al.  Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. , 2010, Biomaterials.

[7]  Qingming Luo,et al.  HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. , 2010, Small.

[8]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[9]  T. Aizawa,et al.  Peptide mimics of epidermal growth factor (EGF) with antagonistic activity. , 2005, Journal of biotechnology.

[10]  T. Schneider-Merck,et al.  Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor1 , 2007, The Journal of Immunology.

[11]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[12]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[13]  S. Seal,et al.  Protonated nanoparticle surface governing ligand tethering and cellular targeting. , 2009, ACS nano.

[14]  T Lammers,et al.  Tumour-targeted nanomedicines: principles and practice , 2008, British Journal of Cancer.

[15]  Xinying Wu,et al.  Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. , 2010, Biomaterials.

[16]  J. Gariépy,et al.  A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  Qingming Luo,et al.  Biomimetic nanocarrier for direct cytosolic drug delivery. , 2009, Angewandte Chemie.

[18]  Gang Zheng,et al.  Enhanced Cancer-Targeted Delivery Using Engineered High-density Lipoprotein-Based Nanocarriers , 2007 .

[19]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[20]  G Poste,et al.  Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[21]  U. Gatzemeier Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer. , 2003, Oncology.

[22]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.